Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TARGINIQ vs ANEXSIA 7.5/650
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.
FDA-approved: Management of severe chronic pain requiring daily around-the-clock opioid treatment, in patients who have responded to and tolerated oxycodone and require treatment for opioid-induced constipation.,Off-label: Not specified
Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.
1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.
Oxycodone terminal half-life is 3.5-4.0 hours; naloxone half-life is 1-1.5 hours. The prolonged-release formulation yields a longer apparent half-life, supporting twice-daily dosing.
Hydrocodone: Terminal half-life 3.8-7.2 hours (mean 5.6 h). Acetaminophen: 1.5-2.5 hours (therapeutic) but prolonged to >4 hours in overdose with hepatotoxicity risk.
Oxycodone: primarily hepatic via CYP3A4 and CYP2D6. Naloxegol: primarily hepatic via CYP3A4.
Hydrocodone: CYP3A4 and CYP2D6; acetaminophen: primarily liver glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3), with minor CYP2E1 oxidation.
Oxycodone is primarily excreted renally as noroxycodone and free oxycodone; naloxone undergoes extensive hepatic metabolism and is excreted renally as naloxone-3-glucuronide. For TARGINIQ, approximately 87% of the dose is eliminated in urine: 19% as unchanged oxycodone, 1% as unchanged naloxone, and the remainder as metabolites. Fecal excretion accounts for ~10%.
Hydrocodone: Renal elimination of metabolites (hydromorphone, norhydrocodone) and unchanged drug accounts for ~60-90% of clearance. Acetaminophen: ~85% of dose is excreted in urine as glucuronide and sulfate conjugates; 5-10% unchanged; 2-5% as mercapturate.
Oxycodone: 45% bound primarily to albumin. Naloxone: approximately 40% bound predominantly to albumin.
Hydrocodone: ~36% bound to serum proteins. Acetaminophen: 10-25% bound (minimal binding).
Oxycodone: Vd 2.6 L/kg, indicating extensive tissue distribution. Naloxone: Vd 2.1 L/kg.
Hydrocodone: Vd ~3-5 L/kg (wide distribution). Acetaminophen: Vd ~0.9-1.0 L/kg (primarily body water).
Oral bioavailability of oxycodone: 60-87% (first-pass metabolism). Naloxone oral bioavailability: <2% due to extensive first-pass hepatic metabolism, allowing local gastrointestinal effect without significant systemic opioid antagonism.
Oral: Hydrocodone ~70-80% (variable first-pass). Acetaminophen ~63-89% (mean 75-80%).
For GFR <60 m L/min: initiate at 50% of usual dose and titrate cautiously. For GFR <30 m L/min: consider alternative therapy; if used, reduce starting dose by 50% and monitor closely. Not recommended in end-stage renal disease (GFR <15 m L/min).
Cr Cl <30 m L/min: contraindicated; Cr Cl 30-60 m L/min: maximum 3 tablets per day; given the hydrocodone component, avoid in severe renal impairment.
Child-Pugh Class A: no adjustment required. Child-Pugh Class B: initiate at 50% of usual dose and titrate cautiously. Child-Pugh Class C: contraindicated due to risk of naloxone accumulation and CNS effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50% and monitor; Child-Pugh Class C: contraindicated due to hydrocodone.
Not recommended for use in pediatric patients (≤18 years) due to lack of safety and efficacy data.
Not recommended in pediatric patients due to risk of respiratory depression; for ages <18, contraindicated.
Initiate at the lower end of the dosing range (e.g., 1 tablet every 12 hours) and titrate cautiously. Monitor for signs of CNS depression, constipation, and respiratory depression. Consider baseline renal and hepatic function for dose adjustments.
Initiate with lowest effective dose, monitor for respiratory depression and constipation; maximum 4 tablets per day in patients >65 years.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of even one dose of TARGINIQ, especially by children, can cause fatal respiratory depression; neonatal opioid withdrawal syndrome; opioid-induced hyperalgesia and allodynia; concomitant use with CYP3A4 inhibitors or discontinuation of CYP3A4 inducers may increase naloxegol exposure and risk of adverse reactions.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion (especially in children) can be fatal; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction (concomitant use with CYP3A4 inhibitors may increase hydrocodone levels); risk of medication errors (confusion between different strengths).
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Opioid-induced hyperalgesia and allodynia,CYP3A4 inhibitor/inducer interactions with naloxegol,Gastrointestinal obstruction: naloxegol is contraindicated in patients with known or suspected gastrointestinal obstruction,Risk of severe opioid withdrawal symptoms with abrupt discontinuation or naloxegol dose increase
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; risk of serotonin syndrome with serotonergic drugs; adrenal insufficiency; hypotension; seizures; gastrointestinal obstruction; severe cutaneous reactions (acetaminophen); hepatotoxicity (acetaminophen overdose); acute abdominal conditions; impaired mental/physical abilities; elderly/debilitated patients; renal/hepatic impairment.
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Known or suspected gastrointestinal obstruction,Concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) with naloxegol,Hypersensitivity to oxycodone, naloxegol, or any component of the formulation
Significant respiratory depression; acute or severe bronchial asthma (without monitoring or resuscitative equipment); known or suspected gastrointestinal obstruction (including paralytic ileus); hypersensitivity to hydrocodone or acetaminophen; use with MAOIs or within 14 days of such therapy.
Take on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid grapefruit juice and other CYP3A4 inhibitors in food, as they may increase naloxegol levels.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and additive CNS depression. Grapefruit juice may increase hydrocodone absorption; consider avoiding. No other significant food interactions.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube defects at high doses. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal at birth.
FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no clear teratogenicity. Acetaminophen is generally safe, but high doses may be hepatotoxic.
Oxycodone and naloxone are excreted in breast milk. Oxycodone M/P ratio approximately 3.2. Use with caution; monitor infant for respiratory depression and sedation. Consider risk of infant opioid exposure.
Oxycodone: M/P ratio ~0.8-3; present in milk; risk of neonatal sedation. Acetaminophen: M/P ~0.8-1, low risk. Avoid due to oxycodone; consider alternative analgesic.
Pregnancy may increase clearance of oxycodone; dose adjustments may be required. However, no specific guidelines. Use lowest effective dose; avoid prolonged use. Taper if discontinuing to prevent withdrawal.
Increased clearance of oxycodone in pregnancy may require increased dose; acetaminophen pharmacokinetics unchanged. Adjust based on pain control and withdrawal risk.
TARGINIQ (naloxegol) is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It does not cross the blood-brain barrier, so it does not reverse central analgesia or precipitate opioid withdrawal. Contraindicated in patients with known or suspected gastrointestinal obstruction. Administer on an empty stomach at least 1 hour before or 2 hours after a meal. Avoid use with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) as they increase naloxegol exposure. Dose adjustments needed for moderate or severe hepatic impairment.
Fixed-dose combination of hydrocodone bitartrate (7.5 mg) and acetaminophen (650 mg). Hydrocodone is a schedule II controlled substance with high abuse potential. Acetaminophen hepatotoxicity risk increases above 3 g/day; prescribe no more than 4 doses per day. Monitor for respiratory depression, especially in opioid-naïve patients. Avoid in severe hepatic impairment. Use with caution in patients with COPD, sleep apnea, or concurrent CNS depressants. Consider naloxone co-prescription if high opioid dose or concurrent benzodiazepine use.
Take TARGINIQ on an empty stomach, at least 1 hour before or 2 hours after eating.,Do not crush or chew the tablet; swallow it whole with water.,If you miss a dose, skip it and take the next dose at the regular time. Do not take two doses at once.,Common side effects include abdominal pain, diarrhea, nausea, gas, and headache. Call your doctor if you have severe or persistent symptoms.,Seek immediate medical attention if you have severe stomach pain, vomiting, or if you are unable to pass stool (possible bowel obstruction).,Inform your doctor about all medications you take, especially strong CYP3A4 inhibitors like certain antibiotics or antifungals.,TARGINIQ does not affect the pain relief from your opioid medication; continue taking your pain medicine as prescribed.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose or frequency.,Do not take with alcohol or other medications containing acetaminophen.,May cause drowsiness or dizziness; avoid driving or operating machinery until effects are known.,Store securely out of reach of children and others; dispose of unused tablets properly.,Seek emergency care for difficulty breathing, severe sedation, or signs of allergic reaction.,Do not abruptly stop after prolonged use; withdrawal symptoms may occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TARGINIQ vs ANEXSIA 7.5/650, answered by our medical review team.
TARGINIQ is a Opioid Analgesic Combination that works by TARGINIQ combines naloxegol, a peripherally acting mu-opioid receptor antagonist (PAMORA), with oxycodone, a full mu-opioid receptor agonist. Naloxegol reduces opioid-induced constipation by blocking opioid effects in the gastrointestinal tract without affecting central analgesia.. ANEXSIA 7.5/650 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception; acetaminophen inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TARGINIQ and ANEXSIA 7.5/650 depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TARGINIQ is: 1 tablet orally every 12 hours, each tablet containing oxycodone hydrochloride 10 mg and naloxone hydrochloride 5 mg (as naloxone hydrochloride dihydrate). Dose may be titrated based on analgesic requirements; maximum daily dose: oxycodone 80 mg and naloxone 40 mg.. The standard adult dose of ANEXSIA 7.5/650 is: 1 tablet orally every 4 to 6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TARGINIQ and ANEXSIA 7.5/650 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TARGINIQ is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS). First trimester: Limited data; animal studies show increased risk of neural tube. ANEXSIA 7.5/650 is classified as Category C. FDA Category C. First trimester: Possible increased risk of cardiac defects with oxycodone. Second/third trimester: Chronic use may lead to neonatal opioid withdrawal syndrome; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.